MedTrace Logo

Efficacy of Early Rhythm Control in AF With TR Patients

NCT07607093 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5800

Last updated 2026-05-26

No results posted yet for this study

Summary

Atrial fibrillation is frequently accompanied by tricuspid regurgitation and may contribute to right atrial and tricuspid annular remodeling, leading to progression of tricuspid regurgitation and adverse clinical outcomes. However, whether early rhythm control improves prognosis in patients with atrial fibrillation and tricuspid regurgitation remains unclear. This study will compare early rhythm control with usual care in these patients, using a composite outcome of cardiac death, heart failure admission, stroke, and tricuspid valve surgery.

Conditions

  • Atrial Fibrillation (AF)
  • Tricuspid Regurgitation (TR)

Interventions

DRUG

Anti-arrhythmic drugs for rhythm control

flecainide, propafenone, pilsicainide, sotalol, amiodarone, dronedarone

PROCEDURE

DC cardioversion, catheter ablation for rhythm control

Direct-current cardioversion may be performed to acutely restore sinus rhythm, particularly in patients with persistent atrial fibrillation or symptomatic rhythm deterioration. Catheter ablation may be considered as a more definitive rhythm-control strategy to reduce atrial fibrillation burden and maintain sinus rhythm over the long term.

OTHER

Usual care

General management without atrial fibrillation rhythm control treatment.(Observation without additional medication, or heart rate control treatment if necessary)

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-18
Primary Completion
2027-02-28
Completion
2027-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07607093 on ClinicalTrials.gov